Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free VCYT Stock Alerts

Veracyte (VCYT) Financials

Veracyte logo
$44.88 +1.45 (+3.34%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$44.90 +0.02 (+0.05%)
As of 04:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Veracyte

Annual Income Statements for Veracyte

This table shows Veracyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -34 -31 -31 -23 -13 -35 -76 -37 -74 24 66
Consolidated Net Income / (Loss)		 -34 -31 -31 -23 -13 -35 -76 -37 -74 24 66
Net Income / (Loss) Continuing Operations		 -34 -31 -31 -23 -13 -35 -76 -37 -74 24 66
Total Pre-Tax Income 		-34 -32 -31 -23 -13 -35 -82 -36 -77 26 68
Total Operating Income		 -33 -29 -27 -22 -15 -35 -82 -41 -86 16 58
Total Gross Profit		 28 40 44 59 84 76 145 176 230 298 363
Total Revenue		 50 65 72 92 120 117 220 297 361 446 517
Operating Revenue		 50 65 72 92 120 117 220 297 361 446 517
Total Cost of Revenue		 21 25 28 33 37 41 74 121 131 148 155
Operating Cost of Revenue		 21 25 28 33 37 41 74 102 113 136 144
Total Operating Expenses		 61 68 70 81 99 111 227 236 334 294 315
Selling, General & Admin Expense		 23 24 23 24 29 37 101 73 86 111 111
Marketing Expense		 25 28 32 41 54 52 80 98 101 95 100
Research & Development Expense		 13 15 14 15 15 17 30 41 57 69 71
Amortization Expense		 0.80 1.07 1.07 1.07 1.40 5.10 16 21 21 15 13
Impairment Charge		 - - - - - - 0.00 3.32 68 3.37 21
Total Other Income / (Expense), net		 -0.38 -2.76 -4.94 -0.77 2.53 0.48 0.25 4.65 9.18 9.60 10
Other Income / (Expense), net		 - - - 1.20 2.53 0.48 0.25 4.65 9.18 9.60 10
Income Tax Expense		 - - - - 0.00 0.00 -6.09 0.13 -2.21 1.61 1.85
Basic Earnings per Share		 ($1.30) ($1.09) ($0.91) ($0.62) ($0.27) ($0.66) ($1.11) ($0.51) ($1.02) $0.32 $0.84
Weighted Average Basic Shares Outstanding		 25.99M 28.83M 33.93M 37.02M 46.14M 53.24M 67.89M 71.55M 72.64M 76.48M 78.58M
Diluted Earnings per Share		 ($1.30) ($1.09) ($0.91) ($0.62) ($0.27) ($0.66) ($1.11) ($0.51) ($1.02) $0.31 $0.82
Weighted Average Diluted Shares Outstanding		 25.99M 28.83M 33.93M 37.02M 46.14M 53.24M 67.89M 71.55M 72.64M 78.16M 80.57M
Weighted Average Basic & Diluted Shares Outstanding		 25.99M 28.83M 33.93M 37.02M 46.14M 53.24M 71.22M 72.15M 75.07M 77.94M 79.46M

Quarterly Income Statements for Veracyte

This table shows Veracyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -28 -1.86 5.73 15 5.11 7.05 -0.98 19 41 29 25
Consolidated Net Income / (Loss)		 -28 -1.86 5.73 15 5.11 7.05 -0.98 19 41 29 25
Net Income / (Loss) Continuing Operations		 -28 -1.86 5.73 15 5.11 7.05 -0.98 19 41 29 25
Total Pre-Tax Income 		-30 -1.91 7.36 17 3.44 7.43 1.25 19 41 30 27
Total Operating Income		 -36 -4.66 4.61 12 4.18 2.90 -5.27 23 37 23 23
Total Gross Profit		 60 62 78 79 76 80 90 91 102 101 109
Total Revenue		 98 97 114 116 119 114 130 132 141 139 150
Operating Revenue		 98 97 114 116 119 114 130 132 141 139 150
Total Cost of Revenue		 38 34 37 37 43 35 40 41 39 38 42
Operating Cost of Revenue		 29 31 34 34 37 32 38 38 36 35 39
Total Operating Expenses		 104 70 76 70 77 79 98 71 67 81 88
Selling, General & Admin Expense		 24 26 32 26 27 34 32 27 17 24 27
Marketing Expense		 25 24 24 23 25 24 25 24 26 27 28
Research & Development Expense		 19 16 16 18 19 18 16 16 21 27 29
Amortization Expense		 4.56 3.65 3.79 3.80 3.61 3.21 3.29 3.33 3.33 3.29 3.16
Impairment Charge		 32 0.43 0.00 0.19 2.75 - 21 0.00 - - 0.00
Total Other Income / (Expense), net		 5.04 2.75 2.76 4.83 -0.73 4.52 6.52 -4.06 3.44 7.33 3.54
Other Income / (Expense), net		 5.04 2.75 2.76 4.83 -0.73 4.52 6.52 -4.06 3.44 7.33 3.54
Income Tax Expense		 -2.18 -0.04 1.63 1.69 -1.67 0.38 2.23 -0.25 -0.52 1.27 1.03
Basic Earnings per Share		 ($0.38) ($0.02) $0.07 $0.20 $0.07 $0.09 ($0.01) $0.24 $0.52 $0.36 $0.32
Weighted Average Basic Shares Outstanding		 72.64M 74.76M 76.54M 77.01M 76.48M 78.03M 78.39M 78.73M 78.58M 79.54M 79.97M
Diluted Earnings per Share		 ($0.38) ($0.02) $0.07 $0.19 $0.07 $0.09 ($0.01) $0.24 $0.50 $0.35 $0.31
Weighted Average Diluted Shares Outstanding		 72.64M 74.76M 77.16M 78.46M 78.16M 80.06M 78.39M 79.69M 80.57M 81.31M 82.06M
Weighted Average Basic & Diluted Shares Outstanding		 75.07M 76.45M 76.81M 77.50M 77.94M 78.31M 78.67M 79.05M 79.46M 79.79M 80.39M

Annual Cash Flow Statements for Veracyte

This table details how cash moves in and out of Veracyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 4.07 20 -25 44 81 190 -176 -19 62 23 124
Net Cash From Operating Activities		 -27 -28 -24 -14 -3.23 -9.71 -32 7.54 44 75 136
Net Cash From Continuing Operating Activities		 -27 -28 -24 -14 -3.23 -9.71 -32 7.54 44 75 136
Net Income / (Loss) Continuing Operations		 -34 -31 -31 -23 -13 -35 -76 -37 -74 24 66
Consolidated Net Income / (Loss)		 -34 -31 -31 -23 -13 -35 -76 -37 -74 24 66
Depreciation Expense		 2.25 3.51 3.84 3.92 4.12 7.94 20 26 27 23 21
Amortization Expense		 0.05 -0.78 0.47 0.03 0.08 - - - -0.47 -0.35 -3.27
Non-Cash Adjustments To Reconcile Net Income		 5.79 7.05 8.22 6.18 11 16 26 34 105 47 70
Changes in Operating Assets and Liabilities, net		 -1.35 -6.41 -5.44 -0.65 -5.88 1.03 -1.23 -16 -13 -19 -18
Net Cash From Investing Activities		 -6.70 -4.21 -1.32 -1.87 -43 -3.84 -739 -29 15 -56 -9.21
Net Cash From Continuing Investing Activities		 -6.70 -4.21 -1.32 -1.87 -43 -3.84 -739 -29 15 -56 -9.21
Purchase of Property, Plant & Equipment		 -6.17 -4.21 -1.76 -1.87 -2.76 -2.84 -5.38 -8.55 -9.96 -11 -9.68
Acquisitions		 0.00 - 0.00 0.00 -40 0.00 -737 0.00 0.00 5.01 0.00
Purchase of Investments		 - - - 0.00 0.00 -1.00 0.00 -34 -20 -50 -150
Sale and/or Maturity of Investments		 - - - - - 0.00 0.00 13 45 0.00 153
Other Investing Activities, net		 -0.53 - - - - - - - 0.00 0.00 -2.85
Net Cash From Financing Activities		 38 52 -0.22 59 127 204 596 3.49 2.84 4.90 -4.22
Net Cash From Continuing Financing Activities		 38 52 -0.22 59 127 204 596 3.49 2.84 4.90 -4.22
Other Financing Activities, net		 0.48 0.93 0.36 4.46 14 9.86 2.50 4.78 2.84 4.90 -4.22
Effect of Exchange Rate Changes		 - - - - - 0.00 -1.51 -0.59 0.16 -0.42 0.72

Quarterly Cash Flow Statements for Veracyte

This table details how cash moves in and out of Veracyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 14 -7.06 27 38 -35 -53 33 96 47 -99 36
Net Cash From Operating Activities		 16 -8.97 30 30 25 5.36 34 45 53 35 46
Net Cash From Continuing Operating Activities		 16 -8.97 30 30 25 5.36 34 45 53 35 46
Net Income / (Loss) Continuing Operations		 -28 -1.86 5.73 15 5.11 7.05 -0.98 19 41 29 25
Consolidated Net Income / (Loss)		 -28 -1.86 5.73 15 5.11 7.05 -0.98 19 41 29 25
Depreciation Expense		 6.34 5.59 5.74 5.88 6.25 5.36 5.49 5.27 5.30 5.43 4.84
Amortization Expense		 - - - - - -0.88 - - -0.65 -0.61 -0.72
Non-Cash Adjustments To Reconcile Net Income		 39 10 11 8.66 17 10 29 17 14 14 15
Changes in Operating Assets and Liabilities, net		 -1.45 -23 6.80 0.28 -3.52 -16 0.36 6.46 -7.67 -12 1.42
Net Cash From Investing Activities		 -2.50 2.88 -2.77 -2.24 -54 -52 -0.22 48 -5.43 -128 -14
Net Cash From Continuing Investing Activities		 -2.50 2.88 -2.77 -2.24 -54 -52 -0.22 48 -5.43 -128 -14
Purchase of Property, Plant & Equipment		 -2.50 -2.13 -2.77 -2.24 -4.14 -1.82 -1.29 -2.79 -3.78 -2.96 -2.86
Purchase of Investments		 - 0.00 - - -50 -50 -50 - -50 -125 -60
Net Cash From Financing Activities		 0.65 -0.86 -0.01 10 -4.51 -6.48 -0.57 2.98 -0.15 -6.63 4.14
Net Cash From Continuing Financing Activities		 0.65 -0.86 -0.01 10 -4.51 -6.48 -0.57 2.98 -0.15 -6.63 4.14
Other Financing Activities, net		 0.65 -0.86 -0.01 10 -4.51 -6.48 -0.57 2.98 -0.15 -6.63 4.14
Effect of Exchange Rate Changes		 0.30 -0.11 -0.06 0.15 -0.40 0.07 0.57 0.06 0.01 -0.06 -0.03
Cash Income Taxes Paid		 0.43 0.00 - 1.19 1.03 0.12 1.43 0.84 - 0.16 1.35

Annual Balance Sheets for Veracyte

This table presents Veracyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 75 101 79 121 275 457 1,188 1,156 1,115 1,300 1,406
Total Current Assets		 48 74 54 97 188 376 243 249 286 372 488
Cash & Equivalents		 39 59 34 78 159 349 173 154 216 239 363
Short-Term Investments		 - - - - - - 3.96 25 0.00 50 50
Accounts Receivable		 3.50 8.76 13 13 19 18 41 44 40 47 45
Inventories, net		 3.77 3.48 5.32 3.40 6.81 4.66 11 14 16 22 21
Prepaid Expenses		 1.44 2.06 2.00 2.39 2.24 3.20 13 11 13 15 10
Plant, Property, & Equipment, net		 10 11 9.69 8.94 8.93 8.99 15 18 21 23 22
Total Noncurrent Assets		 17 16 15 15 79 72 930 890 809 905 895
Goodwill		 1.06 1.06 1.06 1.06 2.73 2.73 708 696 703 746 767
Intangible Assets		 15 14 13 12 65 60 203 175 89 102 89
Other Noncurrent Operating Assets		 0.16 0.13 0.33 1.09 10 9.24 18 19 16 57 39
Total Liabilities & Shareholders' Equity		 75 101 79 121 275 457 1,188 1,156 1,115 1,300 1,406
Total Liabilities		 24 41 41 41 36 36 91 81 71 124 96
Total Current Liabilities		 15 12 12 13 17 17 64 63 61 79 60
Short-Term Debt		 - - 0.00 1.36 1.41 0.00 3.81 6.06 2.66 17 1.33
Accounts Payable		 5.09 2.42 3.85 2.52 2.33 3.12 12 12 13 8.63 4.59
Accrued Expenses		 8.69 9.11 8.18 9.19 14 12 39 38 38 44 49
Current Deferred Revenue		 0.95 - - - 0.00 0.37 4.65 2.61 2.01 1.67 1.16
Other Current Liabilities		 - - - 0.00 - 1.59 3.86 4.26 5.21 7.52 4.05
Total Noncurrent Liabilities		 9.27 30 29 28 18 19 27 19 9.56 45 37
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - 0.00 5.59 4.53 0.73 1.23 0.65
Other Noncurrent Operating Liabilities		 - - - 0.00 18 18 21 14 8.83 44 36
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 51 60 37 80 239 421 1,097 1,075 1,044 1,176 1,310
Total Preferred & Common Equity		 51 60 37 80 239 421 1,097 1,075 1,044 1,176 1,310
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 51 60 37 80 239 421 1,097 1,075 1,044 1,176 1,310
Common Stock		 200 240 248 314 486 703 1,469 1,500 1,536 1,656 1,695
Retained Earnings		 -149 -180 -211 -234 -247 -282 -357 -394 -468 -444 -378
Accumulated Other Comprehensive Income / (Loss)		 - - - - - 0.00 -15 -31 -24 -36 -8.21

Quarterly Balance Sheets for Veracyte

This table presents Veracyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2022 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 1,126 1,161 1,125 1,200 1,234 1,275 1,315 1,344 1,368 1,436 1,486
Total Current Assets		 239 259 271 290 321 357 383 415 449 522 575
Cash & Equivalents		 170 191 202 209 236 274 186 219 316 263 300
Short-Term Investments		 0.00 0.00 0.00 - - - 101 101 51 176 186
Accounts Receivable		 40 42 39 47 50 49 54 51 48 50 54
Inventories, net		 14 12 16 18 19 20 24 25 20 21 23
Prepaid Expenses		 15 14 14 16 16 14 18 18 15 12 13
Plant, Property, & Equipment, net		 17 19 19 22 22 21 23 19 19 23 22
Total Noncurrent Assets		 870 883 834 888 891 897 910 911 900 892 890
Goodwill		 677 699 693 754 752 762 754 773 767 767 767
Intangible Assets		 177 165 124 116 113 109 99 96 92 86 83
Other Noncurrent Operating Assets		 16 19 17 17 25 25 55 40 38 39 40
Total Liabilities & Shareholders' Equity		 1,126 1,161 1,125 1,200 1,234 1,275 1,315 1,344 1,368 1,436 1,486
Total Liabilities		 78 78 71 81 102 99 120 123 110 92 98
Total Current Liabilities		 58 58 57 58 72 70 75 76 72 56 63
Short-Term Debt		 7.10 3.36 2.57 6.93 7.35 7.39 14 13 14 0.98 0.66
Accounts Payable		 11 13 13 12 12 9.67 16 11 5.51 6.91 8.02
Accrued Expenses		 32 34 35 30 43 44 36 44 48 43 48
Current Deferred Revenue		 3.86 2.38 2.21 2.60 2.20 2.03 1.71 1.45 0.42 0.75 0.60
Other Current Liabilities		 4.14 5.09 5.11 6.07 7.26 7.35 7.42 6.41 4.28 4.35 5.78
Total Noncurrent Liabilities		 19 20 14 23 29 29 45 47 38 36 35
Noncurrent Deferred & Payable Income Tax Liabilities		 4.34 4.71 3.64 1.34 1.48 1.47 1.24 1.30 1.21 0.64 0.64
Other Noncurrent Operating Liabilities		 15 16 9.98 22 28 27 44 45 37 35 35
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,048 1,083 1,054 1,119 1,133 1,176 1,195 1,221 1,258 1,344 1,388
Total Preferred & Common Equity		 1,048 1,083 1,054 1,119 1,133 1,176 1,195 1,221 1,258 1,344 1,388
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,048 1,083 1,054 1,119 1,133 1,176 1,195 1,221 1,258 1,344 1,388
Common Stock		 1,492 1,521 1,528 1,618 1,627 1,646 1,661 1,671 1,685 1,702 1,720
Retained Earnings		 -390 -410 -440 -470 -464 -449 -437 -438 -419 -349 -323
Accumulated Other Comprehensive Income / (Loss)		 -54 -28 -34 -29 -31 -21 -29 -12 -8.22 -8.22 -7.94

Annual Metrics And Ratios for Veracyte

This table displays calculated financial ratios and metrics derived from Veracyte's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 29.62% 31.48% 10.55% 27.87% 30.82% -2.40% 86.85% 35.09% 21.76% 23.46% 16.01%
EBITDA Growth		 -12.48% 16.36% 14.74% 23.13% 50.84% -221.05% -130.14% 83.08% -370.75% 199.55% 76.76%
EBIT Growth		 -15.38% 13.93% 7.86% 20.73% 40.11% -177.08% -133.89% 55.39% -110.32% 133.60% 164.92%
NOPAT Growth		 -15.38% 13.93% 7.86% 16.22% 31.96% -133.95% -131.44% 49.84% -108.84% 125.20% 271.40%
Net Income Growth		 -14.74% 6.96% 1.13% 25.82% 45.22% -177.08% -116.46% 51.62% -103.51% 132.44% 174.89%
EPS Growth		 4.41% 16.15% 16.51% 31.87% 56.45% -144.44% -68.18% 54.05% -100.00% 130.39% 164.52%
Operating Cash Flow Growth		 2.41% -3.77% 14.53% 43.46% 76.10% -200.46% -225.62% 123.83% 486.89% 69.82% 81.51%
Free Cash Flow Firm Growth		 30.50% -0.39% 25.91% 16.23% -245.27% 75.42% -5,867.08% 99.12% 252.12% -571.50% 204.68%
Invested Capital Growth		 48.15% 53.05% 11.21% 8.44% 169.09% -11.71% 1,179.80% -2.25% -8.01% 8.74% -0.61%
Revenue Q/Q Growth		 3.87% 6.92% 1.90% 7.17% 3.42% 4.27% 17.57% 4.57% 5.22% 4.80% 4.44%
EBITDA Q/Q Growth		 1.11% 12.26% -4.54% 18.07% -37.91% 4.76% 0.60% 52.75% -122.90% 220.10% 61.76%
EBIT Q/Q Growth		 0.32% 12.93% -9.82% 16.59% -26.15% 1.70% -5.16% 24.10% -54.52% 415.07% 119.93%
NOPAT Q/Q Growth		 0.32% 12.93% -9.82% 11.84% -51.47% 0.35% -5.49% 14.40% -54.01% 191.85% 132.24%
Net Income Q/Q Growth		 0.38% 10.32% -14.97% 18.83% -52.79% -1.71% -3.40% 15.46% -48.94% 360.44% 118.86%
EPS Q/Q Growth		 5.11% 12.80% -13.75% 23.46% -58.82% 4.35% 0.00% 10.53% -45.71% 321.43% 110.26%
Operating Cash Flow Q/Q Growth		 17.21% -5.27% -7.09% 25.34% 48.27% 4.63% 16.36% 20.81% 15.12% 13.57% 25.92%
Free Cash Flow Firm Q/Q Growth		 5.39% 2.61% -2.68% -2.45% -283.20% 77.89% 1.45% -128.57% 254.49% 19.67% 110.54%
Invested Capital Q/Q Growth		 2.89% 11.93% 5.99% 15.62% 130.62% -9.16% -2.50% 1.95% -2.80% -0.69% -0.57%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 56.57% 60.88% 60.81% 64.05% 69.66% 64.71% 66.11% 59.24% 63.62% 66.88% 70.10%
EBITDA Margin		 -62.96% -40.05% -30.89% -18.57% -6.98% -22.95% -28.27% -3.54% -13.69% 11.04% 16.70%
Operating Margin		 -67.60% -44.25% -36.88% -24.16% -12.57% -30.12% -37.31% -13.85% -23.76% 3.62% 11.17%
EBIT Margin		 -67.60% -44.25% -36.88% -22.86% -10.47% -29.71% -37.20% -12.28% -21.22% 5.78% 13.19%
Profit (Net Income) Margin		 -68.08% -48.18% -43.09% -25.00% -10.47% -29.71% -34.42% -12.33% -20.61% 5.42% 12.83%
Tax Burden Percent		 99.59% 99.36% 98.49% 100.00% 100.00% 100.00% 92.55% 100.37% 97.12% 93.76% 97.29%
Interest Burden Percent		 101.13% 109.57% 118.62% 109.33% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.24% 2.71%
Return on Invested Capital (ROIC)		 -170.17% -96.95% -69.92% -53.38% -18.91% -32.23% -11.53% -3.15% -6.94% 1.75% 6.24%
ROIC Less NNEP Spread (ROIC-NNEP)		 -138.60% -64.61% -13.02% -28.03% -16.97% -28.23% -4.56% 1.34% 0.45% -1.94% 3.28%
Return on Net Nonoperating Assets (RNNOA)		 97.40% 40.36% 5.87% 14.05% 11.02% 21.66% 1.57% -0.21% -0.08% 0.43% -0.90%
Return on Equity (ROE)		 -72.77% -56.59% -64.05% -39.32% -7.89% -10.57% -9.96% -3.37% -7.02% 2.17% 5.34%
Cash Return on Invested Capital (CROIC)		 -208.98% -138.87% -80.54% -61.47% -110.54% -19.79% -182.54% -0.88% 1.41% -6.63% 6.85%
Operating Return on Assets (OROA)		 -47.78% -32.68% -29.54% -21.11% -6.37% -9.53% -9.93% -3.11% -6.75% 2.13% 5.04%
Return on Assets (ROA)		 -48.12% -35.58% -34.50% -23.08% -6.37% -9.53% -9.19% -3.12% -6.55% 2.00% 4.90%
Return on Common Equity (ROCE)		 -72.77% -56.59% -64.05% -39.32% -7.89% -10.57% -9.96% -3.37% -7.02% 2.17% 5.34%
Return on Equity Simple (ROE_SIMPLE)		 -65.76% -52.63% -83.29% -28.84% -5.26% -8.29% -6.89% -3.40% -7.13% 2.05% 0.00%
Net Operating Profit after Tax (NOPAT)		 -23 -20 -19 -16 -11 -25 -57 -29 -60 15 56
NOPAT Margin		 -47.32% -30.98% -25.82% -16.91% -8.80% -21.09% -26.12% -9.70% -16.63% 3.40% 10.87%
Net Nonoperating Expense Percent (NNEP)		 -31.58% -32.34% -56.91% -25.35% -1.94% -4.00% -6.97% -4.49% -7.39% 3.68% 2.97%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -2.66% -5.74% 1.27% 4.29%
Cost of Revenue to Revenue		 43.43% 39.12% 39.19% 35.95% 30.34% 35.29% 33.89% 40.76% 36.38% 33.12% 29.90%
SG&A Expenses to Revenue		 45.62% 36.55% 32.09% 26.04% 24.12% 31.26% 46.17% 24.69% 23.88% 24.81% 21.42%
R&D to Revenue		 25.85% 23.54% 19.29% 16.11% 12.34% 14.64% 13.60% 13.69% 15.87% 15.55% 13.69%
Operating Expenses to Revenue		 124.18% 105.13% 97.70% 88.21% 82.22% 94.84% 103.42% 79.60% 92.49% 65.85% 60.99%
Earnings before Interest and Taxes (EBIT)		 -33 -29 -27 -21 -13 -35 -82 -36 -77 26 68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -31 -26 -22 -17 -8.40 -27 -62 -10 -49 49 86
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.89 3.63 5.97 6.39 5.69 6.73 2.67 1.58 1.92 2.61 2.54
Price to Tangible Book Value (P/TBV)		 5.69 4.87 9.62 7.65 7.94 7.90 15.75 8.33 7.96 9.36 7.34
Price to Revenue (P/Rev)		 4.02 3.32 3.09 5.54 11.33 24.12 13.33 5.74 5.57 6.88 6.44
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 127.14 50.16
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.79% 1.99%
Enterprise Value to Invested Capital (EV/IC)		 10.04 7.26 7.64 15.20 14.78 34.48 2.99 1.70 2.16 3.10 3.25
Enterprise Value to Revenue (EV/Rev)		 3.33 2.80 2.97 5.01 10.02 21.15 12.54 5.16 4.97 6.27 5.64
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 56.84 33.78
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 108.63 42.76
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 184.77 51.88
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 203.04 40.60 37.24 21.40
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 147.49 0.00 47.27
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.10 0.43 0.68 0.37 0.01 0.00 0.00 0.01 0.00 0.01 0.00
Long-Term Debt to Equity		 0.10 0.43 0.68 0.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.70 -0.62 -0.45 -0.50 -0.65 -0.77 -0.34 -0.16 -0.18 -0.22 -0.28
Leverage Ratio		 1.51 1.59 1.86 1.70 1.24 1.11 1.08 1.08 1.07 1.09 1.09
Compound Leverage Factor		 1.53 1.74 2.20 1.86 1.24 1.11 1.08 1.08 1.07 1.09 1.09
Debt to Total Capital		 8.87% 29.99% 40.41% 26.79% 0.87% 0.19% 0.35% 0.56% 0.25% 1.42% 0.10%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 1.25% 0.58% 0.00% 0.35% 0.56% 0.25% 1.42% 0.10%
Long-Term Debt to Total Capital		 8.87% 29.99% 40.41% 25.54% 0.29% 0.19% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.13% 70.01% 59.59% 73.21% 99.13% 99.81% 99.65% 99.44% 99.75% 98.58% 99.90%
Debt to EBITDA		 -0.16 -0.98 -1.14 -1.71 -0.25 -0.03 -0.06 -0.58 -0.05 0.35 0.02
Net Debt to EBITDA		 1.10 1.30 0.39 2.86 18.72 12.93 2.79 16.46 4.33 -5.54 -4.77
Long-Term Debt to EBITDA		 -0.16 -0.98 -1.14 -1.63 -0.08 -0.03 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.21 -1.27 -1.36 -1.88 -0.20 -0.03 -0.07 -0.21 -0.04 1.12 0.02
Net Debt to NOPAT		 1.46 1.68 0.47 3.14 14.85 14.07 3.02 6.01 3.56 -18.00 -7.32
Long-Term Debt to NOPAT		 -0.21 -1.27 -1.36 -1.79 -0.07 -0.03 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.93 1.08 -0.10 5.79 22.66 47.40 18.95 12.45 16.78 15.04 21.22
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.25 6.38 4.48 7.42 10.74 22.39 3.79 3.97 4.66 4.73 8.15
Quick Ratio		 2.89 5.89 3.87 6.98 10.23 21.92 3.41 3.56 4.19 4.27 7.63
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -29 -21 -18 -62 -15 -908 -8.00 12 -57 62
Operating Cash Flow to CapEx		 -437.39% -664.66% -1,818.63% -721.50% -118.26% -342.30% -588.19% 88.14% 443.95% 665.33% 1,408.57%
Free Cash Flow to Firm to Interest Expense		 -76.11 -10.48 -4.33 -9.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -71.34 -10.15 -4.84 -6.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -87.65 -11.68 -5.11 -7.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.71 0.74 0.80 0.92 0.61 0.32 0.27 0.25 0.32 0.37 0.38
Accounts Receivable Turnover		 15.11 10.62 6.70 7.11 7.41 6.22 7.33 6.94 8.56 10.26 11.34
Inventory Turnover		 5.76 7.03 6.41 7.58 7.16 7.23 9.37 9.47 8.64 7.79 7.31
Fixed Asset Turnover		 6.84 5.97 6.80 9.88 13.47 13.11 18.23 18.08 18.86 20.48 22.91
Accounts Payable Turnover		 3.44 6.78 8.98 10.39 15.08 15.23 9.61 9.96 10.57 13.68 23.38
Days Sales Outstanding (DSO)		 24.16 34.37 54.46 51.34 49.27 58.70 49.82 52.61 42.66 35.58 32.18
Days Inventory Outstanding (DIO)		 63.36 51.91 56.95 48.14 51.01 50.46 38.96 38.54 42.26 46.83 49.92
Days Payable Outstanding (DPO)		 105.97 53.82 40.63 35.14 24.20 23.97 37.96 36.65 34.53 26.68 15.61
Cash Conversion Cycle (CCC)		 -18.45 32.46 70.79 64.35 76.07 85.20 50.81 54.49 50.40 55.73 66.49
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 16 25 28 30 82 72 922 902 829 902 898
Invested Capital Turnover		 3.60 3.13 2.71 3.16 2.15 1.53 0.44 0.33 0.42 0.51 0.57
Increase / (Decrease) in Invested Capital		 5.34 8.72 2.82 2.36 51 -9.56 850 -21 -72 73 -5.49
Enterprise Value (EV)		 165 183 214 461 1,206 2,485 2,754 1,530 1,796 2,797 2,916
Market Capitalization		 199 216 222 510 1,364 2,833 2,927 1,703 2,009 3,069 3,328
Book Value per Share		 $1.85 $2.13 $1.09 $1.97 $4.90 $7.28 $15.43 $14.98 $14.30 $15.17 $16.57
Tangible Book Value per Share		 $1.26 $1.59 $0.68 $1.65 $3.52 $6.19 $2.62 $2.85 $3.46 $4.23 $5.73
Total Capital		 56 85 62 109 242 422 1,100 1,081 1,047 1,193 1,311
Total Debt		 4.99 26 25 29 2.10 0.81 3.81 6.06 2.66 17 1.33
Total Long-Term Debt		 4.99 26 25 28 0.69 0.81 0.00 0.00 0.00 0.00 0.00
Net Debt		 -34 -34 -8.65 -49 -157 -349 -173 -173 -214 -272 -412
Capital Expenditures (CapEx)		 6.17 4.21 1.32 1.87 2.73 2.84 5.38 8.55 9.96 11 9.68
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.01 2.75 8.01 7.26 12 9.53 5.60 13 11 21 17
Debt-free Net Working Capital (DFNWC)		 33 62 42 85 172 359 183 192 227 311 430
Net Working Capital (NWC)		 33 62 42 84 170 359 179 186 224 294 428
Net Nonoperating Expense (NNE)		 10 11 12 7.44 2.01 10 18 7.80 14 -9.00 -10
Net Nonoperating Obligations (NNO)		 -35 -34 -9.25 -49 -158 -349 -174 -174 -215 -274 -412
Total Depreciation and Amortization (D&A)		 2.30 2.74 4.31 3.95 4.20 7.94 20 26 27 23 18
Debt-free, Cash-free Net Working Capital to Revenue		 -12.14% 4.23% 11.13% 7.89% 10.23% 8.12% 2.55% 4.46% 2.93% 4.75% 3.26%
Debt-free Net Working Capital to Revenue		 67.05% 95.40% 58.23% 92.66% 142.58% 305.49% 83.26% 64.78% 62.88% 69.68% 83.10%
Net Working Capital to Revenue		 67.05% 95.40% 58.23% 91.18% 141.41% 305.49% 81.52% 62.73% 62.15% 65.87% 82.85%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.30) ($1.09) ($0.91) ($0.62) ($0.27) ($0.66) ($1.11) ($0.51) ($1.02) $0.32 $0.84
Adjusted Weighted Average Basic Shares Outstanding		 27.85M 33.85M 34.29M 41.11M 49.74M 67.00M 67.89M 71.55M 72.64M 76.48M 78.58M
Adjusted Diluted Earnings per Share		 ($1.30) ($1.09) ($0.91) ($0.62) ($0.27) ($0.66) ($1.11) ($0.51) ($1.02) $0.31 $0.82
Adjusted Weighted Average Diluted Shares Outstanding		 27.85M 33.85M 34.29M 41.11M 49.74M 67.00M 67.89M 71.55M 72.64M 78.16M 80.57M
Adjusted Basic & Diluted Earnings per Share		 ($1.30) ($1.09) ($0.91) ($0.62) ($0.27) ($0.66) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 25.99M 28.83M 33.93M 37.02M 46.14M 53.24M 71.22M 72.15M 75.07M 77.94M 79.46M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -20 -19 -16 -11 -25 -57 -26 -12 18 76
Normalized NOPAT Margin		 -47.32% -30.98% -25.82% -16.91% -8.80% -21.09% -26.12% -8.91% -3.38% 4.10% 14.73%
Pre Tax Income Margin		 -68.37% -48.49% -43.75% -25.00% -10.47% -29.71% -37.20% -12.28% -21.22% 5.78% 13.19%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -88.53 -10.45 -5.37 -10.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -61.97 -7.31 -3.76 -7.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -104.84 -11.97 -5.64 -11.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -78.28 -8.84 -4.03 -8.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Veracyte

This table displays calculated financial ratios and metrics derived from Veracyte's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 79,458,427.00 79,792,647.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 79,458,427.00 79,792,647.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.36 0.32
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 22.29% 17.50% 26.69% 28.58% 20.81% 18.20% 13.75% 13.82% 18.55% 21.49% 15.49%
EBITDA Growth		 -874.83% 359.11% 1,023.77% 201.23% 140.17% 247.37% -48.55% 6.29% 384.70% 192.16% 438.26%
EBIT Growth		 -785.56% 76.42% 188.93% 156.59% 111.30% 489.31% -83.02% 12.11% 1,080.19% 303.53% 2,021.84%
NOPAT Growth		 -555.11% 55.65% 163.66% 148.65% 124.95% 184.53% 15.11% 115.06% 507.52% 687.24% 434.73%
Net Income Growth		 -636.03% 76.96% 168.25% 151.17% 118.07% 478.06% -117.09% 26.28% 704.79% 307.36% 2,701.02%
EPS Growth		 -533.33% 81.82% 158.33% 146.34% 118.42% 550.00% -114.29% 26.32% 614.29% 288.89% 3,200.00%
Operating Cash Flow Growth		 59.61% -312.80% 77.40% 111.44% 57.69% 159.80% 13.63% 49.37% 114.41% 556.75% 36.37%
Free Cash Flow Firm Growth		 179.33% -205.66% -199.82% -596.30% -240.02% 90.92% 99.43% 164.19% 163.58% 1,700.43% 695.01%
Invested Capital Growth		 -8.01% 2.38% 0.00% 6.44% 8.74% 0.54% 1.02% -0.56% -0.61% -1.52% -0.91%
Revenue Q/Q Growth		 8.98% -1.38% 18.16% 1.25% 2.39% -3.51% 13.71% 1.31% 6.65% -1.11% 8.09%
EBITDA Q/Q Growth		 -7.51% 115.26% 255.76% 73.49% -57.34% 31.91% -47.31% 258.44% 87.46% -23.17% -11.93%
EBIT Q/Q Growth		 -2.35% 93.74% 485.80% 128.88% -79.56% 115.74% -83.17% 1,411.12% 115.12% -26.23% -11.51%
NOPAT Q/Q Growth		 -11.87% 86.89% 210.09% 201.27% -42.64% -55.56% 49.91% 462.87% 62.03% -42.42% 1.83%
Net Income Q/Q Growth		 4.47% 93.41% 407.62% 164.30% -66.26% 37.83% -113.91% 2,052.76% 115.02% -30.24% -11.21%
EPS Q/Q Growth		 7.32% 94.74% 450.00% 171.43% -63.16% 28.57% -111.11% 2,500.00% 108.33% -30.00% -11.43%
Operating Cash Flow Q/Q Growth		 9.75% -157.65% 429.86% 1.31% -18.15% -78.14% 526.73% 33.19% 17.49% -33.03% 30.13%
Free Cash Flow Firm Q/Q Growth		 432.38% -151.77% -3,566.61% 95.09% -50.20% 96.64% -128.95% 655.75% 52.23% -17.37% -14.88%
Invested Capital Q/Q Growth		 -2.80% 10.35% -1.36% 0.60% -0.69% 2.03% -0.89% -0.98% -0.57% 0.93% -0.28%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 61.08% 67.51% 68.09% 68.19% 63.93% 69.46% 68.97% 69.22% 72.51% 72.74% 72.21%
EBITDA Margin		 -24.58% 3.80% 11.45% 19.62% 8.17% 11.17% 5.18% 18.32% 32.20% 25.02% 20.38%
Operating Margin		 -36.16% -4.81% 4.03% 10.37% 3.52% 2.54% -4.05% 17.40% 26.45% 16.28% 15.29%
EBIT Margin		 -31.03% -1.97% 6.43% 14.54% 2.90% 6.49% 0.96% 14.32% 28.89% 21.55% 17.64%
Profit (Net Income) Margin		 -28.81% -1.92% 5.01% 13.08% 4.31% 6.16% -0.75% 14.51% 29.26% 20.64% 16.96%
Tax Burden Percent		 92.85% 97.69% 77.90% 89.95% 148.50% 94.87% -78.40% 101.31% 101.27% 95.77% 96.11%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 22.10% 10.05% -48.50% 5.13% 178.40% -1.31% -1.27% 4.23% 3.89%
Return on Invested Capital (ROIC)		 -10.56% -1.40% 2.78% 4.51% 2.69% 1.22% 1.68% 9.64% 15.38% 9.25% 9.09%
ROIC Less NNEP Spread (ROIC-NNEP)		 -8.79% -2.11% 0.91% 2.65% 3.14% -0.58% 3.57% 10.96% 14.36% 7.28% 8.23%
Return on Net Nonoperating Assets (RNNOA)		 1.61% 0.38% -0.18% -0.56% -0.69% 0.12% -0.82% -2.80% -3.95% -2.04% -2.50%
Return on Equity (ROE)		 -8.95% -1.02% 2.59% 3.95% 2.00% 1.34% 0.86% 6.84% 11.43% 7.21% 6.59%
Cash Return on Invested Capital (CROIC)		 1.41% -8.54% -210.44% -8.11% -6.63% 1.89% 0.37% 3.24% 6.85% 9.76% 12.40%
Operating Return on Assets (OROA)		 -9.87% -0.63% 2.08% 5.15% 1.07% 2.39% 0.36% 5.37% 11.04% 8.49% 7.01%
Return on Assets (ROA)		 -9.16% -0.61% 1.62% 4.64% 1.59% 2.27% -0.28% 5.44% 11.18% 8.13% 6.73%
Return on Common Equity (ROCE)		 -8.95% -1.02% 2.59% 3.95% 2.00% 1.34% 0.86% 6.84% 11.43% 7.21% 6.59%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -6.09% -4.77% -0.79% 0.00% 2.77% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -3.26 3.59 11 6.20 2.76 4.13 23 38 22 22
NOPAT Margin		 -25.31% -3.37% 3.14% 9.33% 5.23% 2.41% 3.17% 17.63% 26.78% 15.60% 14.69%
Net Nonoperating Expense Percent (NNEP)		 -1.77% 0.71% 1.87% 1.86% -0.44% 1.80% -1.90% -1.32% 1.02% 1.97% 0.86%
Return On Investment Capital (ROIC_SIMPLE)		 -2.37% - - - 0.52% 0.23% 0.33% 1.83% 2.87% 1.61% 1.59%
Cost of Revenue to Revenue		 38.92% 32.49% 31.91% 31.81% 36.07% 30.54% 31.03% 30.78% 27.49% 27.26% 27.79%
SG&A Expenses to Revenue		 24.23% 27.06% 27.74% 22.22% 22.69% 29.53% 24.84% 20.69% 12.35% 17.03% 18.26%
R&D to Revenue		 19.02% 16.49% 14.39% 15.17% 16.26% 15.48% 12.50% 12.12% 14.82% 19.49% 19.59%
Operating Expenses to Revenue		 106.24% 72.32% 66.61% 60.34% 65.24% 69.18% 75.06% 53.87% 47.99% 58.40% 58.75%
Earnings before Interest and Taxes (EBIT)		 -30 -1.91 7.36 17 3.44 7.43 1.25 19 41 30 27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 3.68 13 23 9.70 13 6.74 24 45 35 31
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.92 1.49 1.46 2.22 2.61 1.93 1.73 2.15 2.54 1.90 3.38
Price to Tangible Book Value (P/TBV)		 7.96 6.70 6.18 8.57 9.36 6.77 6.01 6.79 7.34 5.21 8.70
Price to Revenue (P/Rev)		 5.57 4.43 4.15 6.15 6.88 4.99 4.42 5.45 6.44 4.72 8.34
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 127.14 69.93 80.38 89.09 50.16 29.08 40.93
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.79% 1.43% 1.24% 1.12% 1.99% 3.44% 2.44%
Enterprise Value to Invested Capital (EV/IC)		 2.16 1.60 1.58 2.59 3.10 2.21 1.98 2.60 3.25 2.34 4.65
Enterprise Value to Revenue (EV/Rev)		 4.97 3.89 3.57 5.52 6.27 4.40 3.78 4.74 5.64 3.92 7.48
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 152.76 56.84 34.95 34.83 43.99 33.78 19.42 31.32
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 108.63 58.10 62.46 75.72 42.76 23.38 36.21
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 184.77 91.27 143.95 97.01 51.88 28.21 40.26
Enterprise Value to Operating Cash Flow (EV/OCF)		 40.60 39.04 28.37 35.51 37.24 22.79 19.36 21.69 21.40 12.77 23.55
Enterprise Value to Free Cash Flow (EV/FCFF)		 147.49 0.00 0.00 0.00 0.00 117.49 541.83 80.12 47.27 23.79 37.30
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.18 -0.18 -0.20 -0.21 -0.22 -0.21 -0.23 -0.26 -0.28 -0.28 -0.30
Leverage Ratio		 1.07 1.07 1.09 1.08 1.09 1.09 1.10 1.09 1.09 1.08 1.08
Compound Leverage Factor		 1.07 1.07 1.09 1.08 1.09 1.09 1.10 1.09 1.09 1.08 1.08
Debt to Total Capital		 0.25% 0.62% 0.64% 0.62% 1.42% 1.19% 1.09% 1.07% 0.10% 0.07% 0.05%
Short-Term Debt to Total Capital		 0.25% 0.62% 0.64% 0.62% 1.42% 1.19% 1.09% 1.07% 0.10% 0.07% 0.05%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.75% 99.38% 99.36% 99.38% 98.58% 98.81% 98.91% 98.93% 99.90% 99.93% 99.95%
Debt to EBITDA		 -0.05 -0.16 -0.25 0.48 0.35 0.25 0.26 0.25 0.02 0.01 0.00
Net Debt to EBITDA		 4.33 4.56 7.67 -17.35 -5.54 -4.68 -5.92 -6.61 -4.77 -4.01 -3.61
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.04 -0.12 -0.16 -0.45 1.12 0.64 1.07 0.56 0.02 0.01 0.01
Net Debt to NOPAT		 3.56 3.61 4.85 16.18 -18.00 -12.23 -24.45 -14.58 -7.32 -5.83 -4.64
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 16.91 12.25 9.82 16.00 14.99 11.70 10.53 15.03 21.16 17.19 29.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.66 5.00 4.44 5.08 4.73 5.10 5.43 6.23 8.15 9.31 9.16
Quick Ratio		 4.19 4.41 3.96 4.59 4.27 4.54 4.86 5.74 7.63 8.72 8.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 47 -25 -899 -44 -66 -2.23 -5.10 28 43 36 30
Operating Cash Flow to CapEx		 622.83% -420.15% 1,067.69% 1,336.44% 592.22% 294.78% 2,613.14% 1,603.04% 1,391.08% 1,188.89% 1,602.87%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.32 0.32 0.32 0.35 0.37 0.37 0.37 0.37 0.38 0.39 0.40
Accounts Receivable Turnover		 8.56 8.43 7.94 9.66 10.26 9.23 9.48 10.25 11.34 10.43 10.70
Inventory Turnover		 8.64 7.90 6.24 6.87 7.79 6.96 6.87 7.66 7.31 6.90 6.67
Fixed Asset Turnover		 18.86 18.74 17.93 21.01 20.48 21.02 23.46 24.70 22.91 23.98 27.76
Accounts Payable Turnover		 10.57 9.43 9.94 11.22 13.68 10.64 12.93 20.53 23.38 13.93 16.33
Days Sales Outstanding (DSO)		 42.66 43.27 45.95 37.80 35.58 39.56 38.52 35.62 32.18 35.00 34.10
Days Inventory Outstanding (DIO)		 42.26 46.19 58.50 53.11 46.83 52.43 53.13 47.66 49.92 52.90 54.74
Days Payable Outstanding (DPO)		 34.53 38.69 36.71 32.52 26.68 34.31 28.24 17.78 15.61 26.20 22.36
Cash Conversion Cycle (CCC)		 50.40 50.77 67.74 58.39 55.73 57.69 63.41 65.50 66.49 61.70 66.49
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 829 915 903 908 902 920 912 903 898 906 904
Invested Capital Turnover		 0.42 0.42 0.89 0.48 0.51 0.50 0.53 0.55 0.57 0.59 0.62
Increase / (Decrease) in Invested Capital		 -72 21 903 55 73 4.98 9.23 -5.10 -5.49 -14 -8.27
Enterprise Value (EV)		 1,796 1,461 1,428 2,348 2,797 2,038 1,810 2,348 2,916 2,121 4,202
Market Capitalization		 2,009 1,664 1,657 2,615 3,069 2,311 2,117 2,701 3,328 2,559 4,686
Book Value per Share		 $14.30 $14.90 $14.81 $15.31 $15.17 $15.33 $15.59 $15.99 $16.57 $16.92 $17.40
Tangible Book Value per Share		 $3.46 $3.31 $3.50 $3.97 $4.23 $4.38 $4.49 $5.06 $5.73 $6.18 $6.75
Total Capital		 1,047 1,126 1,140 1,183 1,193 1,209 1,234 1,271 1,311 1,345 1,389
Total Debt		 2.66 6.93 7.35 7.39 17 14 13 14 1.33 0.98 0.66
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -214 -202 -229 -267 -272 -273 -307 -353 -412 -438 -485
Capital Expenditures (CapEx)		 2.50 2.13 2.77 2.24 4.14 1.82 1.29 2.79 3.78 2.96 2.86
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 11 30 20 20 21 35 31 24 17 28 27
Debt-free Net Working Capital (DFNWC)		 227 239 256 294 311 322 352 391 430 467 513
Net Working Capital (NWC)		 224 232 249 287 294 308 338 377 428 466 512
Net Nonoperating Expense (NNE)		 3.44 -1.40 -2.15 -4.35 1.09 -4.29 5.11 4.11 -3.48 -7.02 -3.41
Net Nonoperating Obligations (NNO)		 -215 -203 -230 -268 -274 -275 -309 -354 -412 -438 -485
Total Depreciation and Amortization (D&A)		 6.34 5.59 5.74 5.88 6.25 5.36 5.49 5.27 4.65 4.82 4.12
Debt-free, Cash-free Net Working Capital to Revenue		 2.93% 8.02% 5.06% 4.67% 4.75% 7.56% 6.46% 4.89% 3.26% 5.17% 4.89%
Debt-free Net Working Capital to Revenue		 62.88% 63.73% 64.10% 69.11% 69.68% 69.57% 73.40% 78.90% 83.10% 86.21% 91.24%
Net Working Capital to Revenue		 62.15% 61.89% 62.26% 67.37% 65.87% 66.47% 70.60% 76.15% 82.85% 86.03% 91.13%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.38) ($0.02) $0.07 $0.20 $0.07 $0.09 ($0.01) $0.24 $0.52 $0.36 $0.32
Adjusted Weighted Average Basic Shares Outstanding		 72.64M 74.76M 76.54M 77.01M 76.48M 78.03M 78.39M 78.73M 78.58M 79.54M 79.97M
Adjusted Diluted Earnings per Share		 ($0.38) ($0.02) $0.07 $0.19 $0.07 $0.09 ($0.01) $0.24 $0.50 $0.35 $0.31
Adjusted Weighted Average Diluted Shares Outstanding		 72.64M 74.76M 77.16M 78.46M 78.16M 80.06M 78.39M 79.69M 80.57M 81.31M 82.06M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 75.07M 76.45M 76.81M 77.50M 77.94M 78.31M 78.67M 79.05M 79.46M 79.79M 80.39M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.43 -2.96 3.59 11 4.85 2.76 11 16 26 22 22
Normalized NOPAT Margin		 -2.47% -3.06% 3.14% 9.47% 4.09% 2.41% 8.19% 12.18% 18.51% 15.60% 14.69%
Pre Tax Income Margin		 -31.03% -1.97% 6.43% 14.54% 2.90% 6.49% 0.96% 14.32% 28.89% 21.55% 17.64%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Veracyte (NASDAQ: VCYT) has shown substantial operating improvement across the reported quarters, although recent cash deployment, dilution and acquisition-related goodwill remain important risks. Revenue increased from $75.6 million in Q3 2022 to $150.3 million in Q2 2026, nearly doubling over the period. The company has also moved from recurring operating losses in 2022 and early 2023 to sustained operating profitability in the more recent quarters.

Q2 2026 revenue rose 8.1% from $139.1 million in Q1 2026 and 15.5% from $130.2 million in Q2 2025. Gross profit increased to $108.5 million, producing a gross margin of approximately 72.2%, compared with roughly 69.0% in Q2 2025 and 65.6% in Q3 2022. Operating income was $23.0 million, or about 15.3% of revenue, while net income was $25.5 million, equal to diluted earnings per share of $0.31.

  • Strong long-term revenue growth: Quarterly revenue climbed from $75.6 million in Q3 2022 to $150.3 million in Q2 2026, with growth continuing despite a modest decline in Q1 2026.
  • Improving gross margins: Q2 2026 gross margin reached approximately 72.2%, up from 69.0% a year earlier and 65.6% in Q3 2022, indicating favorable revenue mix or operating efficiency.
  • Sustained profitability has emerged: Veracyte reported operating income in each quarter from Q3 2024 through Q2 2026, apart from the impact of the Q2 2025 impairment charge. Q2 2026 operating income was $23.0 million.
  • Healthy operating cash generation: Cash flow from operations increased to $45.8 million in Q2 2026 from $33.6 million in Q2 2025. Operating cash flow has remained positive in every quarter provided since Q3 2022.
  • Strong liquidity and limited debt: Cash and equivalents plus short-term investments totaled approximately $485.2 million at June 30, 2026, compared with total liabilities of only $98.0 million. Short-term debt was just $662,000.
  • Retained losses are narrowing: The retained earnings deficit improved from approximately $469.985 million in Q1 2024 to $323.433 million in Q2 2026, reflecting the company’s return to profitability.
  • Cash balances are being actively invested: Veracyte purchased $125.0 million of investments in Q1 2026 and $60.0 million in Q2 2026. These transactions reduced or redirected cash but appear to represent portfolio management rather than operating cash burn.
  • Results include restatements and calculated periods: Several historical 2023–2025 statements were marked as restated or calculated in the supplied data, so investors should rely on the latest company filings when comparing historical trends.
  • Net income has been volatile: Q2 2026 net income of $25.5 million declined from $28.7 million in Q1 2026 and $41.1 million in Q4 2025. Earnings have also been affected by fluctuations in other income and nonrecurring impairment charges.
  • High acquisition-related asset concentration and dilution: Goodwill totaled $767.2 million, or more than half of total assets, creating impairment risk if acquired businesses underperform. Diluted weighted-average shares increased from 72.8 million in Q3 2023 to 82.1 million in Q2 2026, which can limit per-share earnings growth.

Overall, the statements point to a stronger and more financially durable Veracyte than the company shown in 2022 and early 2023. The key items for investors to monitor are whether revenue growth remains strong, whether operating margins stay above 15%, and whether cash investments, goodwill and share issuance continue to expand without weakening returns to shareholders.

09/03/26 03:40 AM ETAI Generated. May Contain Errors.

Veracyte Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Veracyte's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Veracyte's net income appears to be on a downward trend, with a most recent value of $66.35 million in 2025, falling from -$33.70 million in 2015. The previous period was $24.14 million in 2024. Find out what analysts predict for Veracyte in the coming months.

Veracyte's total operating income in 2025 was $57.78 million, based on the following breakdown:
  • Total Gross Profit: $362.53 million
  • Total Operating Expenses: $315.42 million

Over the last 10 years, Veracyte's total revenue changed from $49.50 million in 2015 to $517.15 million in 2025, a change of 944.7%.

Veracyte's total liabilities were at $96.44 million at the end of 2025, a 22.3% decrease from 2024, and a 301.9% increase since 2015.

In the past 10 years, Veracyte's cash and equivalents has ranged from $33.89 million in 2017 to $362.58 million in 2025, and is currently $362.58 million as of their latest financial filing in 2025.

Over the last 10 years, Veracyte's book value per share changed from 1.85 in 2015 to 16.57 in 2025, a change of 794.2%.


Related Companies

Financial statements for NASDAQ:VCYT last updated on 7/31/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel